SINGLE DOSE AMPHETAMINE EFFECTS IN SCHIZOPHRENIA

本研究旨在确定那些慢性精神分裂症患者， 可能是慢性多巴胺受体激动剂 治疗 使用交叉随机顺序设计，精神分裂症患者被给予 单次口服安非他明 患者受到“保护”， 持续使用氟哌啶醇治疗导致其精神病恶化。 我们 假设精神分裂症的缺陷症状可能是 皮质多巴胺能衰竭 由于皮质多巴胺受体 多巴胺能神经元主要为D1亚型，中脑边缘多巴胺能神经元主要为D2亚型 亚型，我们假设安非他明，一种非特异性多巴胺 给予服用相对特异性D2的人的间接激动剂 阻断剂氟哌啶醇可增强D1功能。 21名患者中有6名在服用安非他明当天的情况比 到安慰剂日 这六个人的共同点是大脑室到大脑 与无反应者相比， 组 长期给药的研究正在进行中。

This study is designed to identify those chronic schizophrenic patients who might be especially appropriate candidates for chronic dopamine agonist treatment. Using a crossover random order design, schizophrenic patients are given a single oral dose of amphetamine. Patients are "protected" from possible exacerbation of their psychosis by ongoing treatment with haloperidol. We hypothesize that the deficit symptoms of schizophrenia may be a reflection of cortical dopaminergic failure. Since cortical dopamine receptors are mostly of the D1 subtype and mesolimbic dopaminergic neurones are of the D2 subtype, we hypothesize that amphetamine, a non-specific dopamine indirector agonist given to a person taking the relatively specific D2 blocking agent haloperidol might enhance D1 function. Six of 21 patients were found to be better on the amphetamine day compared to the placebo day. These six had in common greater ventricular to brain ratio and greater enhancement of blink rate compared to the non responsive group. Studies with chronic administration are in progress.